HIV associated nephropathy medical therapy

Revision as of 16:13, 3 February 2017 by Krzys617 (talk | contribs)
Jump to navigation Jump to search

HIV associated nephropathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating HIV associated nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

KUB X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

HIV associated nephropathy medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of HIV associated nephropathy medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on HIV associated nephropathy medical therapy

CDC on HIV associated nephropathy medical therapy

HIV associated nephropathy medical therapy in the news

Blogs on HIV associated nephropathy medical therapy

Directions to Hospitals Treating HIV associated nephropathy

Risk calculators and risk factors for HIV associated nephropathy medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2];Associate Editor(s)-in-Chief: Krzysztof Wierzbicki M.D. [3]

Overview

Medical Therapy

Corticosteroids

The use of Corticosteroids in the treatment of HIV-associated nephropathy in a retrospective study between 1992 and 1996 has shown that prednisone given at 60mg/d for 2 to 11 weeks was shown to decrease serum creatinine and proteinuria. In other retrospective studies, prednisone given at a dose of 1mg/kg for a span of 2 to 6 weeks has been shown to prolong renal survival before the need of hemodialysis.

ACE Inhibitors

The use of an ACE inhibitor such as Fosinopril has been linked to higher renal survival before progression to end-stage renal disease. The effects where studied in a prospective non-randomized trial between 1993 and 1995. The study showed that the use of an ACE inhibitor decreased the rate patients with HIV-associated nephropathy would develop end-stage renal disease over 5 years. In another retrospective study, the use of captopril with a reverse transcriptase inhibitor prolonged renal survival time by about 156 days as compared to 37 days for those not taking an ACE inhibitor.

HAART

With the advent of HAART therapy the renal survival time in patients with HIV-associated nephropathy has greatly slowed the progression to end-stage renal disease. In a case-control study, the use of antiretroviral therapy for a span of 56 days, has been shown to have a protective effect on the renal. In a another retrospective cohort trial, the use of antiretroviral therapy has showed a survival rate of 18.4 months.[1]

References

  1. Atta MG, Gallant JE, Rahman MH, Nagajothi N, Racusen LC, Scheel PJ; et al. (2006). "Antiretroviral therapy in the treatment of HIV-associated nephropathy". Nephrol Dial Transplant. 21 (10): 2809–13. doi:10.1093/ndt/gfl337. PMID 16864598.

Template:WH Template:WS